Clinical Trial Update: Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial of Rebeccamycin Analog as second-line therapy for extensive-stage or limited-stage small cell lung cancer; the study was terminated and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Limited-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Rebeccamycin analog (rebeccamycin analog)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-01-01